Skip to main content

Table 2 Observed responses in central composite design for PLGA-CURC formulation

From: Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy

Exp. No Wt. of PLGA (mg) PVA conc. (% w/v) Ethyl Acetate (ml) Particle Size (nm) Polydispersity Encapsulation efficiency (%) Drug loading (%)
1 50 1 2 125.6 0.135 73.4 11.1
2 120 1 2 142.5 0.148 63.35 11.4
3 50 3 2 108.5 0.125 73.84 11.3
4 120 3 2 144.5 0.143 63.86 13.5
5 50 1 5 81.5 0.097 83.25 14.9
6 120 1 5 133.8 0.116 85.5 13.2
7 50 3 5 103.7 0.115 83.54 10.5
8 120 3 5 136.7 0.135 84.8 15.8
9 26.14 2 3.5 133.3 0.138 63.25 5.5
10 143.86 2 3.5 198.8 0.172 53.46 9.4
11 85 0.32 3.5 158.8 0.164 88.85 13.6
12 85 3.68 3.5 149.5 0.155 88.25 13.8
13 85 2 0.98 176.9 0.093 53.35 14.5
14 85 2 6.02 77.8 0.067 63.78 15.2
15 85 2 3.5 112.5 0.135 86.95 11.8
16 85 2 3.5 121.6 0.148 90.35 12.6
17 85 2 3.5 119.8 0.135 91.46 10.5
18 85 2 3.5 118.6 0.147 93.54 11.9
19 85 2 3.5 129.6 0.128 90.34 12.8
20 85 2 3.5 119.7 0.172 86.27 12.9